Single use systems (SUS) refers to biopharmaceutical manufacturing equipment designed to be used once and then discarded. Single-use technologies offer an extremely efficient and cost-effective way to manufacture biopharmaceuticals, offering significant increases in the product quality. Biopharmaceutical companies worldwide use single-use system to manufacture drugs and vaccines using small/large scale bioreactors. Single-use technologies provide solutions that address the bioprocessing needs in the development and manufacturing of biopharmaceuticals. Moreover, single-use systems (SUS) are being increasingly used as an alternative to stainless-steel equipment for biopharmaceutical manufacturing processes.
Market Statistics:
The global single use system in biopharma manufacturing market is estimated to account for US$ 8,490.8 Mn in terms of value by the end of 2022.
Drivers:
Increase in demand for drugs and vaccines across the globe is expected to augment the growth of the global single use system in biopharma manufacturing market during the forecast period. For instance, due to the ability of biopharmaceuticals to treat previously untreatable diseases, the demand for safe, effective drugs and vaccines is also increasing. In February 2021, Bristol Myers Squibb granted a global exclusive license to develop, manufacture, and commercialize Rockefeller’s novel monoclonal antibody (mAb) duo treatment that neutralizes SARS-CoV-2 virus for therapy or prevention of COVID-19.
Opportunities:
Increase in demand for biopharmaceutical products worldwide is expected to provide lucrative growth opportunities for players in the global single use system in biopharma manufacturing market. In October 2021, Waters Corp. and Sartorius teamed up to implement the BioAccord LC-MS System from Waters as new bioprocess analyzer with data connectivity to Sartorius’ Ambr bioreactor systems to deliver mass spectral data on drug substances, related analytes and cell culture media. This will greatly accelerate and improve the accuracy and the speed of tasks from clone selection to bioprocess optimization.
Restraints:
Qualifying issues related to extractable & leachable are expected to hinder growth of the single use system in biopharma manufacturing market. Due to the extractable and leachable chemicals mixed with the end product, the quality of the biological product could deteriorate. Extractable and leachable components could cause adverse effects on patients' health and product quality. Thus, biopharma products need to be assessed carefully while manufacturing and storing.
To know the latest trends and insights prevalent in the Global Single Use System in Biopharma Manufacturing Market, click the link below:
Global Single Use System in Biopharma Manufacturing Market - Impact of Coronavirus (Covid-19) Pandemic
When it comes to the current COVID-19 situation, single-use technology allows for the rapid development and production of vaccines and therapies, and the outbreak of COVID-19 was a tipping point for single-use systems, with demand for disposable and flexible technology for commercial-scale manufacturing significantly increasing. Amid the race to produce COVID-19 vaccines, DuPont Liveo Healthcare Solutions have been selected by manufacturers around the world for their purity and reliability. From being used in the collection of buffer and active prior to COVID-19 vaccine filtration to being employed in single-use vaccine systems, Liveo solutions have made an impact in the global fight against the COVID-19 pandemic.
Key Takeaways:
The global single use system in biopharma manufacturing market was valued at US$ 7,030.0 Mn in 2021 and is forecast to reach a value of US$ 26,450.3 Mn by 2028 at a CAGR of 20.8% between 2022 and 2028.
Among bioreactor, 1000-2000L segment held dominant position in the global single use system in biopharma manufacturing market in 2021, accounting for 58.3% share in terms of value, increasing approval and launch of new products is expected to propel growth of the segment during the forecast period.
Market Trends:
- Growing investments in the development of drugsand vaccines is expected to drive growth of the single use system in biopharma manufacturing market. In July 2021, Frazier Healthcare and Takeda Pharmaceutical partnered to launch a biopharmaceutical company named HilleVax to develop and market Takeda’s vaccine candidate, HIL-214 (previously TAK-214).
- Ability of biopharmaceuticals to treat previously untreatable diseases is expected to propel growth of the single use system in biopharma manufacturing market. Biopharmaceuticals are widely used to treat cancer, chronic viral hepatitis, inflammatory, and autoimmune diseases. Thus, with the increase in disease burden, demand for biopharmaceuticals is also increasing.
Competitive Landscape:
Major players operating in the global single use system in biopharma manufacturing market include Getinge AB, Rentschler Biopharma SE, Kühner AG, Danaher Corporation, Merck KgaA, Lonza, PBS Biotech Inc., ThermoFisher Scientific, Corning Incorporated, Eppendorf, Pall Corporation, Entegris, and Sartorius AG (Sartorius Stedim Biotech), among others.
Recent Developments:
In September 2021, ThermoFisher Scientific invested around US$ 100 million to establish the dedicated single use technologies (SUT) product manufacturing facility in U.S.
In December 2020, Pall Corporation announced a strategic partnership with Single Use Support GmbH to distribute the RoSS platform which enhances Pall’s integrated solutions and make the RoSS platform more accessible to Biopharma customers around the globe.
In June 2019, Sartorius Stedim Biotech (SSB) announced the launch of the new vessel for its Ambr 250 modular benchtop automated mini bioreactor system. Ambr 250 Modular bioreactor vessel launched for cell and gene therapy applications.
